130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Download search resultsDownload the search results for:
"HIV Preventive Vaccine" [CONDITION] (130 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Condition: HIV Infections
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: rgp120/HIV-1MN
3 Completed Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1 SF-2;   Biological: MTP-PE/MF59
4 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVADV027-00-VP;   Biological: VRC-HIVADV038-00-VP;   Biological: VRC-HIVDNA044-00-VP
5 Active, not recruiting Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins
Condition: HIV Infections
Interventions: Biological: HIV-1 DNA plasmid vaccine;   Biological: HIV-1 recombinant Ad5 vaccine
6 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMGNP (vCP300);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
7 Unknown  HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV MN120TMG (vCP205)
8 Completed A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: MTP-PE/MF59;   Biological: Env 2-3
9 Completed A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
10 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
11 Withdrawn Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP placebo;   Biological: VRC-HIVADV014-00-VP placebo
12 Completed Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP
13 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
14 Completed Safety of the EnvPro HIV Vaccine in Healthy Volunteers
Condition: HIV Infections
Intervention: Biological: EnvPro
15 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
Condition: HIV Infections
Interventions: Biological: gp160 Vaccine (Immuno-AG);   Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: HIVAC-1e
16 Completed Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
Condition: HIV Infections
Interventions: Biological: SAAVI DNA-C2 vaccine;   Biological: SAAVI MVA-C vaccine;   Biological: Placebo
17 Completed HIV-1 Vaccine Test in Uninfected Adult Volunteers
Conditions: Healthy;   HIV Seronegativity
Intervention: Drug: VRC4302
18 Completed A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
Condition: HIV Infections
Intervention: Biological: rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
19 Completed Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers
Conditions: HIV-1;   HIV Infections
Intervention: Biological: MVA.HIVA
20 Completed A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1;   Biological: ALVAC-HIV MN120TMG (vCP205)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years